Abstract
The stimulatory NKG2D lymphocyte receptor together with its tumor-associated ligands enable the immune system to recognize and destroy cancer cells. However, with dynamic changes unfolding, cancers exploit NKG2D and its ligands for immune evasion and suppression. Recent findings have added yet another functional dimension, wherein cancer cells themselves co-opt NKG2D for their own benefit to complement the presence of its ligands for self-stimulation of parameters of tumorigenesis. Those findings are here extended to in vivo tumorigenicity testing by employing orthotopic xenotransplant breast cancer models in mice. Using human cancer lines with ectopic NKG2D expression and RNA interference (RNAi)-mediated protein depletion among other controls, we show that NKG2D self-stimulation has tumor-promoting capacity. NKG2D signals had no notable effects on cancer cell proliferation and survival but acted at the level of angiogenesis, thus promoting tumor growth, tumor cell intravasation and dissemination. NKG2D-mediated effects on tumor initiation may represent another factor in the observed overall enhancement of tumor development. Altogether, these results may have an impact on immunotherapy approaches, which currently do not account for such NKG2D effects in cancer patients and thus could be misdirected as underlying assumptions are incomplete.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nausch N, Cerwenka A . NKG2D ligands in tumor immunity. Oncogene 2008; 27: 5944–5958.
Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727–729.
Lanier LL . Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495–502.
Upshaw JL, Leibson PJ . NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes. Semin Immunol 2006; 18: 167–175.
Gonzalez S, Groh V, Spies T . Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 2006; 298: 121–138.
Eagle RA, Trowsdale J . Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007; 7: 737–744.
Raulet DH, Gasser S, Gowen BG, Deng W, Jung H . Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31: 413–441.
Benitez AC, Dai Z, Mann HH, Reeves RS, Margineantu DH, Gooley TA et al. Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proc Natl Acad Sci USA 2011; 108: 4081–4086.
Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247–256.
Kooijman R . Regulation of apoptosis by insulin-like growth factor (IGF)-1. Cytokine Growth Factor Rev 2006; 17: 305–323.
Kaufman SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG . Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53: 3976–3985.
von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107: 1955–1962.
Cho HM, Rosenblatt JD, Tolba K, Shin SJ, Shin DS, Calfa C et al. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. Cancer Res 2010; 70: 10121–10130.
Zhang T, Sentman CL . Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res 2011; 71: 2066–2076.
Lehner M, Gotz G, Proff J, Schaft N, Dorrie J, Full F et al. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One 2012; 7: e31210.
Song DG, Ye Q, Santoro S, Fang C, Best A, Powell DJ et al. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer Is enhanced by histone deacetylase Inhibition. Hum Gene Ther 2013; 24: 295–305.
Noel A, Simon N, Raus J, Foidart JM . Basement membrane components (matrigel) promote the tumorigenicity of human breast adenocarcinoma MCF7 cells and provide an in vivo model to assess the responsiveness of cells to estrogen. Biochem Pharmacol 1992; 43: 1263–1267.
Jiang B-H, Liu L-Z . PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009; 102: 19–65.
Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL et al. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA 2009; 106: 3913–3918.
Ben-Batalla I, Seoane S, Garcia-Caballero T, Gallego R, Macia M, Gonzalez LO et al. Deregulation of the Pit-1 transcription factor in human breast cancer cells promotes tumor growth and metastasis. J Clin Invest 2010; 120: 4289–4302.
Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T . Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879–6884.
Acknowledgements
We thank Drs Steven Kelly and Sue Knoblaugh and all members of the Comparative Medicine Shared Resource laboratory for their expert veterinarian, pathology and histopathology support; Drs Julie Randolph-Habecker and Peggy Porter for their expert immunohistochemistry and histopathology advice, and all members of the Experimental Histopathology Shared Resource laboratory for their outstanding technical support. AE-G was supported by an Erwin Schrödinger Fellowship from the Austrian Science Fund (FWF; project number J3078). This study was supported by an NIH/NCI Pacific Ovarian Cancer Research Consortium (POCRC) SPORE (P50 CA083636) developmental research program grant (to VG) and NIH/NCI grant R01 CA174470 (to TS).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
El-Gazzar, A., Cai, X., Reeves, R. et al. Effects on tumor development and metastatic dissemination by the NKG2D lymphocyte receptor expressed on cancer cells. Oncogene 33, 4932–4940 (2014). https://doi.org/10.1038/onc.2013.435
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2013.435
Keywords
This article is cited by
-
Tumoral NKG2D alters cell cycle of acute myeloid leukemic cells and reduces NK cell-mediated immune surveillance
Immunologic Research (2016)